S&P 500   4,171.49 (-0.81%)
DOW   32,776.20 (-0.81%)
QQQ   346.67 (-0.95%)
AAPL   178.39 (+0.61%)
MSFT   329.56 (-0.50%)
META   262.33 (-0.07%)
GOOGL   122.93 (-0.60%)
AMZN   119.28 (-1.96%)
TSLA   195.65 (-2.74%)
NVDA   385.49 (-3.89%)
NIO   7.18 (-3.10%)
BABA   77.91 (-0.97%)
AMD   119.66 (-4.48%)
T   15.78 (+0.90%)
F   12.01 (-4.61%)
MU   68.10 (-5.01%)
CGC   0.80 (-5.63%)
GE   100.09 (-2.26%)
DIS   87.22 (-0.68%)
AMC   4.45 (-3.89%)
PFE   37.79 (+2.11%)
PYPL   61.25 (-1.29%)
NFLX   393.39 (+0.10%)
S&P 500   4,171.49 (-0.81%)
DOW   32,776.20 (-0.81%)
QQQ   346.67 (-0.95%)
AAPL   178.39 (+0.61%)
MSFT   329.56 (-0.50%)
META   262.33 (-0.07%)
GOOGL   122.93 (-0.60%)
AMZN   119.28 (-1.96%)
TSLA   195.65 (-2.74%)
NVDA   385.49 (-3.89%)
NIO   7.18 (-3.10%)
BABA   77.91 (-0.97%)
AMD   119.66 (-4.48%)
T   15.78 (+0.90%)
F   12.01 (-4.61%)
MU   68.10 (-5.01%)
CGC   0.80 (-5.63%)
GE   100.09 (-2.26%)
DIS   87.22 (-0.68%)
AMC   4.45 (-3.89%)
PFE   37.79 (+2.11%)
PYPL   61.25 (-1.29%)
NFLX   393.39 (+0.10%)
S&P 500   4,171.49 (-0.81%)
DOW   32,776.20 (-0.81%)
QQQ   346.67 (-0.95%)
AAPL   178.39 (+0.61%)
MSFT   329.56 (-0.50%)
META   262.33 (-0.07%)
GOOGL   122.93 (-0.60%)
AMZN   119.28 (-1.96%)
TSLA   195.65 (-2.74%)
NVDA   385.49 (-3.89%)
NIO   7.18 (-3.10%)
BABA   77.91 (-0.97%)
AMD   119.66 (-4.48%)
T   15.78 (+0.90%)
F   12.01 (-4.61%)
MU   68.10 (-5.01%)
CGC   0.80 (-5.63%)
GE   100.09 (-2.26%)
DIS   87.22 (-0.68%)
AMC   4.45 (-3.89%)
PFE   37.79 (+2.11%)
PYPL   61.25 (-1.29%)
NFLX   393.39 (+0.10%)
S&P 500   4,171.49 (-0.81%)
DOW   32,776.20 (-0.81%)
QQQ   346.67 (-0.95%)
AAPL   178.39 (+0.61%)
MSFT   329.56 (-0.50%)
META   262.33 (-0.07%)
GOOGL   122.93 (-0.60%)
AMZN   119.28 (-1.96%)
TSLA   195.65 (-2.74%)
NVDA   385.49 (-3.89%)
NIO   7.18 (-3.10%)
BABA   77.91 (-0.97%)
AMD   119.66 (-4.48%)
T   15.78 (+0.90%)
F   12.01 (-4.61%)
MU   68.10 (-5.01%)
CGC   0.80 (-5.63%)
GE   100.09 (-2.26%)
DIS   87.22 (-0.68%)
AMC   4.45 (-3.89%)
PFE   37.79 (+2.11%)
PYPL   61.25 (-1.29%)
NFLX   393.39 (+0.10%)
Top-Rated StocksTop-RatedPositive News SentimentPositive News
NASDAQ:ICLR

ICON Public (ICLR) Stock Forecast, Price & News

$208.57
+0.10 (+0.05%)
(As of 11:40 AM ET)
Compare
Today's Range
$206.40
▼
$209.31
50-Day Range
$183.12
▼
$215.91
52-Week Range
$171.43
▼
$249.62
Volume
183,184 shs
Average Volume
577,566 shs
Market Capitalization
$17.09 billion
P/E Ratio
33.75
Dividend Yield
N/A
Price Target
$257.30
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

ICON Public MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
24.0% Upside
$257.30 Price Target
Short Interest
Healthy
1.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.86mentions of ICON Public in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.66%
From $11.88 to $13.74 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

101st out of 1,006 stocks

Commercial Physical Research Industry

5th out of 16 stocks

See Top Rated MarketRank™ Stocks Here

ICLR stock logo

About ICON Public (NASDAQ:ICLR) Stock

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Stock News Headlines

May 31, 2023 | finance.yahoo.com
ICON plc to Attend Upcoming Investor Conferences
May 18, 2023 | americanbankingnews.com
Analysts Set ICON Public Limited (NASDAQ:ICLR) Target Price at $257.30
May 31, 2023 | Edge On The Street (Ad)
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
May 16, 2023 | finance.yahoo.com
ICON releases its 2022 ICON Cares ESG Report
May 8, 2023 | americanbankingnews.com
Financial Comparison: ICON Public (NASDAQ:ICLR) and OmniAb (NASDAQ:OABI)
May 5, 2023 | benzinga.com
Will Chart Analysts Notice Bad Omen on Icon's Chart
May 3, 2023 | americanbankingnews.com
ICON Public Limited Expected to Post Q1 2024 Earnings of $3.18 Per Share (NASDAQ:ICLR)
May 3, 2023 | americanbankingnews.com
Brokers Set Expectations for ICON Public Limited's Q3 2023 Earnings (NASDAQ:ICLR)
May 31, 2023 | Edge On The Street (Ad)
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
May 2, 2023 | americanbankingnews.com
ICON Public (NASDAQ:ICLR) Price Target Lowered to $220.00 at Wells Fargo & Company
May 1, 2023 | msn.com
Baird Maintains Icon (ICLR) Outperform Recommendation
May 1, 2023 | msn.com
Wells Fargo Maintains Icon (ICLR) Equal-Weight Recommendation
May 1, 2023 | markets.businessinsider.com
Baird Maintains Outperform Rating for Icon: Here's What You Need To Know
May 1, 2023 | americanbankingnews.com
ICON Public (NASDAQ:ICLR) PT Lowered to $270.00
May 1, 2023 | americanbankingnews.com
Citigroup Cuts ICON Public (NASDAQ:ICLR) Price Target to $250.00
April 29, 2023 | americanbankingnews.com
ICON Public (NASDAQ:ICLR) Shares Down 5.9%
April 29, 2023 | americanbankingnews.com
ICON Public (NASDAQ:ICLR) Price Target Cut to $263.00 by Analysts at Guggenheim
April 28, 2023 | msn.com
Guggenheim Maintains Icon (ICLR) Buy Recommendation
April 28, 2023 | msn.com
Citigroup Maintains Icon (ICLR) Buy Recommendation
April 28, 2023 | msn.com
ICON Park launches new interactive experience aboard The Wheel
April 27, 2023 | americanbankingnews.com
ICON Public (NASDAQ:ICLR) Sees Strong Trading Volume
April 26, 2023 | finance.yahoo.com
Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates
April 26, 2023 | finance.yahoo.com
ICON Reports First Quarter 2023 Results
April 25, 2023 | americanbankingnews.com
ICON Public (ICLR) Set to Announce Earnings on Wednesday
April 21, 2023 | americanbankingnews.com
ICON Public Limited (NASDAQ:ICLR) Receives $265.70 Average Target Price from Analysts
April 20, 2023 | seekingalpha.com
ICLR ICON Public Limited Company
April 6, 2023 | americanbankingnews.com
ICON Public (NASDAQ:ICLR) PT Lowered to $250.00
See More Headlines
Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Company Calendar

Last Earnings
11/03/2021
Today
5/31/2023
Next Earnings (Estimated)
7/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ICLR
CUSIP
N/A
CIK
1060955
Web
www.iconplc.com
Phone
(531) 291-2000
Fax
353-1247-6260
Employees
41,100
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$257.30
High Stock Price Forecast
$280.00
Low Stock Price Forecast
$220.00
Forecasted Upside/Downside
+23.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$6.18
Trailing P/E Ratio
33.73
Forward P/E Ratio
17.55
P/E Growth
1.2
Net Income
$505.30 million
Net Margins
6.52%
Pretax Margin
7.33%
Return on Equity
11.16%
Return on Assets
5.45%

Debt

Debt-to-Equity Ratio
0.50
Current Ratio
1.18
Quick Ratio
1.18

Sales & Book Value

Annual Sales
$7.74 billion
Price / Sales
2.21
Cash Flow
$18.58 per share
Price / Cash Flow
11.22
Book Value
$105.63 per share
Price / Book
1.97

Miscellaneous

Outstanding Shares
81,930,000
Free Float
45,880,000
Market Cap
$17.08 billion
Optionable
Optionable
Beta
1.12

Social Links


Key Executives

  • Stephen A. Cutler
    Chief Executive Officer & Executive Director
  • Brendan Brennan
    Chief Financial Officer
  • Tom O'Leary
    Chief Information Officer
  • Gregory P. Licholai
    Chief Medical & Innovation Officer
  • Diarmaid Cunningham
    Secretary, Chief Administrative Officer & EVP

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ICLR Stock - Frequently Asked Questions

Should I buy or sell ICON Public stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICLR shares.
View ICLR analyst ratings or view top-rated stocks.

What is ICON Public's stock price forecast for 2023?

10 brokerages have issued twelve-month price targets for ICON Public's stock. Their ICLR share price forecasts range from $220.00 to $280.00. On average, they predict the company's share price to reach $257.30 in the next twelve months. This suggests a possible upside of 23.4% from the stock's current price.
View analysts price targets for ICLR or view top-rated stocks among Wall Street analysts.

How have ICLR shares performed in 2023?

ICON Public's stock was trading at $194.25 on January 1st, 2023. Since then, ICLR shares have increased by 7.3% and is now trading at $208.47.
View the best growth stocks for 2023 here.

When is ICON Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our ICLR earnings forecast.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) released its quarterly earnings data on Wednesday, November, 3rd. The medical research company reported $2.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.16. The medical research company had revenue of $1.87 billion for the quarter, compared to analysts' expectations of $1.84 billion. ICON Public had a trailing twelve-month return on equity of 11.16% and a net margin of 6.52%. ICON Public's revenue was up 166.0% on a year-over-year basis. During the same quarter last year, the business earned $1.72 earnings per share.

What ETFs hold ICON Public's stock?

ETFs with the largest weight of ICON Public (NASDAQ:ICLR) stock in their portfolio include Harbor Health Care ETF (MEDI), iShares MSCI Ireland ETF (EIRL), VanEck Biotech ETF (BBH), Motley Fool Global Opportunities ETF (TMFG), Janus Henderson US Sustainable Equity ETF (SSPX), Invesco ESG NASDAQ Next Gen 100 ETF (QQJG), VictoryShares Nasdaq Next 50 ETF (QQQN) and BNY Mellon Sustainable International Equity ETF (BKIS).

What guidance has ICON Public issued on next quarter's earnings?

ICON Public issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $12.40-$13.05 for the period, compared to the consensus EPS estimate of $12.67. The company issued revenue guidance of $7.94 billion-$8.34 billion, compared to the consensus revenue estimate of $8.14 billion.

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).

What is ICON Public's stock symbol?

ICON Public trades on the NASDAQ under the ticker symbol "ICLR."

Who are ICON Public's major shareholders?

ICON Public's stock is owned by a variety of retail and institutional investors. Top institutional investors include CIBC Private Wealth Group LLC (0.67%), TimesSquare Capital Management LLC (0.25%), Todd Asset Management LLC (0.17%), Globeflex Capital L P (0.06%), Kornitzer Capital Management Inc. KS (0.05%) and Silvercrest Asset Management Group LLC (0.04%).

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ICON Public's stock price today?

One share of ICLR stock can currently be purchased for approximately $208.47.

How much money does ICON Public make?

ICON Public (NASDAQ:ICLR) has a market capitalization of $17.08 billion and generates $7.74 billion in revenue each year. The medical research company earns $505.30 million in net income (profit) each year or $6.18 on an earnings per share basis.

How many employees does ICON Public have?

The company employs 41,100 workers across the globe.

Does ICON Public have any subsidiaries?
The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..
Read More
How can I contact ICON Public?

ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The official website for the company is www.iconplc.com. The medical research company can be reached via phone at (531) 291-2000 or via fax at 353-1247-6260.

This page (NASDAQ:ICLR) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -